Article

T cell invigoration is associated with the clinical response to anti-PD-1 based immunotherapy in non-small cell lung cancer

2023-06-08

Abstract excerpt

<h4>Purpose: </h4> Immune checkpoint inhibitors (ICIs) have been developed for clinical application and proven effective for non-small cell lung cancer (NSCLC). Blockade of the programmed cell death 1 (PD-1) protein can partially reinvigorate circulating exhausted-phenotype CD8+ T cells (Tex cells) in preclinical models, however the clinical implication in anti-PD-1 based immunotherapy in NSCLC is unknown. <h4>Me...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1f9f01f6-bfe4-5d8e-b9c5-b808062cdbc9
DOI: 10.21203/rs.3.rs-3021178/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

T cell invigoration is associated with the clinical response to anti-PD-1 based immunotherapy in non-small cell lung cancerDOI 10.21203/rs.3.rs-3021178/v1Read

Periphery TH/TS ratio and TP53 mutation predict the efficacy of ICI-based therapy in advanced non-small cell lung cancer with high PD-L1 expressionSemantic proximity Read

Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value.Semantic proximity Read

TCF-1+ PD-1+ CD8+T Cells Are Associated With The Response To PD-1 Blockade In Non-Small Cell Lung Cancer PatientsSemantic proximity Read

Association of Lymphocyte Subsets in Advanced Non-Small Cell Lung Cancer Patients with the Efficacy and Prognosis of Immune Checkpoint Inhibitor Therapy: A Retrospective StudySemantic proximity Read

Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients.Semantic proximity Read

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 InhibitorsSemantic proximity Read

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?Semantic proximity Read

BTLA Expression in Stage I–III Non–Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical OutcomesSemantic proximity Read

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.Semantic proximity Read

It is too Early to Say NO IMMUNOTHERAPY for EGFR‐Mutant NSCLC PatientsSemantic proximity Read

Functional and Molecular Characterization of PD1+ Tumor-Infiltrating Lymphocytes From Lung Cancer PatientsSemantic proximity Read

Transformation of a cold to hot tumor and a durable response to immunotherapy in a patient with non-small cell lung cancer after chemoradiotherapy: a case report.Semantic proximity Read